These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2819762)

  • 1. 2-Amino-7-phosphonoheptanoic acid, a selective antagonist of N-methyl-D-aspartate, prevents barbital withdrawal-induced convulsions and the elevation of cerebellar cyclic GMP in dependent rats.
    McCaslin PP; Morgan WW
    Neuropharmacology; 1987 Jul; 26(7A):731-5. PubMed ID: 2819762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased response of cerebellar cGMP to kainate but not NMDA or quisqualate following barbital withdrawal from dependent rats.
    McCaslin PP; Morgan WW
    Eur J Pharmacol; 1989 Dec; 173(2-3):127-32. PubMed ID: 2560429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticonvulsive activity of several excitatory amino acid antagonists against barbital withdrawal-induced spontaneous convulsions.
    McCaslin PP; Morgan WW
    Eur J Pharmacol; 1988 Mar; 147(3):381-6. PubMed ID: 3378564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Amino-7-phosphonoheptanoic acid, a selective N-methyl-D-aspartate antagonist, blocks swim-induced elevation of cerebellar cyclic guanosine monophosphate.
    McCaslin PP; Morgan WW
    Brain Res; 1986 Nov; 398(1):71-4. PubMed ID: 3026565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuously infused 2-amino-7-phosphonoheptanoic acid antagonizes N-methyl-D-aspartate-induced elevations of cyclic GMP in vivo in multiple brain areas and chemically-induced seizure activity.
    McCaslin PP; Morgan WW
    Neuropharmacology; 1986 Aug; 25(8):905-9. PubMed ID: 2877414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of tolerance to chronic barbital treatment in the cerebellar cyclic guanosine monophosphate system and its response to subsequent barbital abstinence.
    Lane SJ; Morgan WW
    J Pharmacol Exp Ther; 1985 Sep; 234(3):569-74. PubMed ID: 2993585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of neurochemical tolerance following chronic barbital treatment.
    Lane SJ; Morgan WW
    Neurobehav Toxicol Teratol; 1985; 7(2):195-7. PubMed ID: 2987720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (+/-)-cis-2,3-Piperidine dicarboxylic acid is a partial N-methyl-D-aspartate agonist in the in vitro rat cerebellar cGMP model.
    Leach MJ; Marden CM; Canning HM
    Eur J Pharmacol; 1986 Feb; 121(2):173-9. PubMed ID: 2870927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 2-amino-7-phosphonoheptanoic acid (APH) on seizure susceptibility in the prepubescent and mature rat.
    Holmes GL; Thompson JL; Carl GF; Gallagher BS; Hoy J; McLaughlin M
    Epilepsy Res; 1990 Mar; 5(2):125-30. PubMed ID: 2158439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased susceptibility of audiogenic rats to barbital withdrawal convulsions.
    Bourn WM; Garrett RL
    Pharmacol Biochem Behav; 1983 Nov; 19(5):839-41. PubMed ID: 6685882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in brain levels of cyclic nucleotides and gamma-aminobutyric acid in barbiturate dependence and withdrawal.
    Lenox RH; Wray HL; Kant GJ; Hawkins TD; Meyerhoff JL
    Eur J Pharmacol; 1979 Apr; 55(2):159-69. PubMed ID: 222596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemia-induced neuronal damage prevented by an N-methyl-D-aspartate antagonist.
    Wieloch T
    Science; 1985 Nov; 230(4726):681-3. PubMed ID: 2996146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of withdrawal from long-term barbital treatment on open-field behaviour and seizure susceptibility of rats.
    Palermo-Neto J; De Lima TC
    Neuropharmacology; 1982 Mar; 21(3):277-81. PubMed ID: 6122187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid.
    Czuczwar SJ; Meldrum B
    Eur J Pharmacol; 1982 Sep; 83(3-4):335-8. PubMed ID: 6293844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of chronic oral administration of barbital on cerebellar cyclic GMP.
    Lane SJ; Morgan WW
    Neuropharmacology; 1984 Jul; 23(7A):779-83. PubMed ID: 6089024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible involvement of NMDA receptor-mediated transmission in barbiturate physical dependence.
    Rabbani M; Wright J; Butterworth AR; Zhou Q; Little HJ
    Br J Pharmacol; 1994 Jan; 111(1):89-96. PubMed ID: 7912157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GABAergic influences on barbital withdrawal induced convulsions.
    Sandoval MR; Palermo-Neto J
    Gen Pharmacol; 1986; 17(4):431-5. PubMed ID: 3758649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 6-hydroxydopamine pretreatment on spontaneous convulsions induced by barbital withdrawal.
    Morgan WW
    Experientia; 1976 Apr; 32(4):489-91. PubMed ID: 944644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of central monoamine compounds on tranylcypromine-induced barbital-withdrawal convulsions.
    Tagashira E; Hiramori T; Nakao K; Urano T; Yanaura S
    Life Sci; 1983 Apr; 32(14):1599-606. PubMed ID: 6682167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Amino-7-phosphonoheptanoic acid inhibits insulin-induced convulsions and striatal aspartate accumulation in rats with frontal cortical ablation.
    Chapman AG; Engelsen B; Meldrum BS
    J Neurochem; 1987 Jul; 49(1):121-7. PubMed ID: 3295120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.